Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

days post last dose, Day 59 Table 4: ISIS 301012 Coadministered with Statins, Laboratory Findings. Number of patients with ALT elevations >/= 3xULN (maximal ALT observed = 211 IU/L). ALT Elevations Single(+) / Placebo 30 mg 100 mg 200 mg 300 mg 400 mg Consecutive(++) (n = 13) (n = 8) (n = 8) (n =16) (n = 8) (n = 8) Primary Endpoint (Day 1 to 59) 0 / 0 0 / 0 0 / 0 1 / 0 0 / 1 1 / 0 Primary Follow-up (Day 60 to 87) 0 / 0 0 / 0 0 / 0 0 / 1 0 / 0 0 / 0 Long term F/U (Day 88 to 199) 0 / 0 0 / 0 0 / 0 0 / 0 NA NA (+) Single = elevation that returned to below 3xULN by the next visit at least 7 days later (++) Consecutive = elevation that was observed in two measures at least 7 days apart Primary endpoint period was 30 days post last dose, Day 59 Primary follow-up period was from primary endpoint to 8 weeks post last dose NA = data not available, cohorts remain in follow-up Presentation Details Date: Monday, March 26, 2007 Session: 820: Clinical Trials of Lipid-Lowering Therapy (4:00 - 5:30 p.m. CT) Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Auditorium B Presentation: 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein Cholesterol and Apolipoprotein B in Hypercholesterolemic Subjects on Statins Not Meeting Target More about Phase 2 Trials for ISIS 301012

Additional data from two studies evaluating ISIS 301012's safety and lipid lowering activity were presented at the ACC. This morning in an ora
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/3/2015)... NEW YORK , Sept. 3,  2015 ... organs are human-made bio-artificial devices, which are ... or support natural organs. These include artificial ... materials such as polymers (polyurethane, polysulfone, and ... used to develop artificial organs. These organs ...
(Date:9/3/2015)... PARK, Calif. , Sept. 3, 2015 ... device company that is providing innovative evidence-based solutions for ... management will be presenting at the Morgan Stanley Global ... York City.  Nevro management is scheduled ... be accessible via a live audio webcast, accessible in ...
(Date:9/3/2015)... , Sept. 3, 2015  As part of ... with heart disease, Marc R. Katz , MD, ... Bon Secours Heart & Vascular Institute implanted the first ... 2015. The patient was selected as part of the ... of 60 elite centers in the United States—and the ...
Breaking Medicine Technology:Global Artificial Organ Market 2015-2019 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 3Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 4
... 2011 / PRNewswire/ -- Fleming Pharmaceuticals, ... iodide product indicated for thyroid protection in radiation emergencies ... necessary to ramp up production to meet increased domestic ... an over-the-counter iodide solution which, when taken orally, saturates ...
... 21, 2011 Scott & White Healthcare today teleconferenced ... to repair an abdominal aortic aneurysm to conference attendees ... in Comparative Education) 2011, is one of the globe,s ... The procedure demonstrated the use of an endograft device ...
Cached Medicine Technology:Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield® 2Scott & White Healthcare Broadcasts Live Surgery to Sao Paolo, Brazil 2
(Date:9/3/2015)... ... September 03, 2015 , ... NanoCytomics LLC ... medical technology company that will bring low-cost cancer pre-screening tests to primary care ... proprietary and automated technology platform detects and measures cellular changes at the nanoscale ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... partner for the Academy of Integrative Health & Medicine (AIHM) Interprofessional Fellowship in ... of Tieraona Low Dog, MD, an internationally renowned educator, physician and thought leader ...
(Date:9/3/2015)... ... September 03, 2015 , ... The ... Experience Conference 2016, to be held April 13-15 at Sheraton Hotel in Dallas, ... bringing together the collective voices of healthcare leaders, staff, physicians, patients and families ...
(Date:9/3/2015)... ... September 03, 2015 , ... Topical BioMedics, Inc., ... destination of his six-month, 10,000 mile journey from Santiago, Chile to Times Square ... calls the “Connecting Las Americas” project—Max crossed six countries in 168 days on ...
(Date:9/3/2015)... ... September 03, 2015 , ... BedJet released a new version ... for pre-order on Kickstarter. Today the BedJet v2 pre-order campaign blazed past ... 0.1% most successful campaigns ever on crowdfunding giant Kickstarter. , Simple to use and ...
Breaking Medicine News(10 mins):Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3
... Switzerland) -- The International AIDS Society (IAS) and the ... the recipients of their third annual joint research fellowships. ... to advance scientific understanding of the linkages between drug ... Young researchers from China and Indonesia will be awarded ...
... most important determinants of an individual,s risk of cancer ... whether and at what ages close relatives were ... screening examinations such as colonoscopies and mammograms. In ... Association a multi-institutional research team reports that changes ...
... , TUESDAY, July 12 (HealthDay News) -- People,s employment ... during the workweek, but men and women are affected differently, ... Institute on Aging measured the levels of physical activity in ... Survey, which gathers data on about 5,000 people each year. ...
... -- Scorching heat and oppressive humidity continued to grip much ... -- and in some cases 100 degrees -- from the ... doctors to warn that high temperatures can cause serious -- ... has ways of keeping itself cool, by letting heat escape ...
... in adults is not related to how they rate ... In a study of self-rated health (SRH) published this ... Lysack, Ph.D., deputy director of WSU,s Institute of Gerontology, ... and Stewart Neufeld, Ph.D., assistant professor in the Institute ...
... a boost were originally developed as temporary measures for ... has improved, these ventricular assist devices commonly operate in ... whose implant this month celebrates its one-year anniversary. , ... cord that protrudes through the patient,s belly is cumbersome ...
Cached Medicine News:Health News:Fellowships for outstanding research in drug use and HIV awarded by IAS and NIDA 2Health News:Changes in family history of cancer can impact screening recommendations 2Health News:Changes in family history of cancer can impact screening recommendations 3Health News:Physical Activity Levels Linked to Employment Status 2Health News:Soaring Temps Can Pose Serious Health Risks 2Health News:Soaring Temps Can Pose Serious Health Risks 3Health News:Severity of spinal cord injury has no impact on how adults rate their health, WSU research finds 2Health News:Wireless power could cut cord for patients with implanted heart pumps 2Health News:Wireless power could cut cord for patients with implanted heart pumps 3
The Lineage acetabular system with ceramic liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
Hemisphere modular Cup....
Cer-Met series II system....
Derived from an extensive study into increasing the range of motion in hip replacement, the cemented SHP acetabular cup is a unique design and is manufactured from ArCom polyethylene....
Medicine Products: